Mesencephalic Astrocyte‐Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin‐Related Modifier (SUMO)ylation‐Related Suppression of NF‐κB/Snail Signaling Pathway and Epithelial‐Mesenchymal Transition

Jun Liu, Zhengsheng Wu, Dan Han, Chuansheng Wei, Yanyan Liang, Tongcui Jiang, Lu Chen, Manqi Sha, Yajie Cao, Fan Huang, Xiaoping Geng, Jishuang Yu, Yujun Shen, Hua Wang, Lijie Feng, Dong Wang, Shengyun Fang, Siying Wang, Yuxian Shen – 30 August 2019

CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis–Driven Hepatocarcinogenesis via ERK‐Dependent PKM2 Nuclear Relocalization and Activation

Tin‐Lok Wong, Kai‐Yu Ng, Kel Vin Tan, Lok‐Hei Chan, Lei Zhou, Noélia Che, Ruby L.C. Hoo, Terence K. Lee, Stéphane Richard, Chung‐Mau Lo, Kwan Man, Pek‐Lan Khong, Stephanie Ma – 30 August 2019

Management of Patients With Erythropoietic Protoporphyria–Related Progressive Liver Disease

Zaid S. Ardalan, Sujievvan Chandran, Abhinav Vasudevan, Peter W. Angus, Andrew Grigg, Simon He, Graeme A. Macdonald, Simone I. Strasser, Courtney J. Tate, Glen A. Kennedy, Adam G. Testro, Paul J. Gow – 30 August 2019 – Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction of protoporphyrin IX (PPIX), which can lead to progressive liver disease characterized by recurrent EPP crises and end‐stage liver disease.

Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute‐on‐Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival

Annabel Blasi, Vishal C. Patel, Jelle Adelmeijer, Sarah Azarian, Maria Hernandez Tejero, Andrea Calvo, Javier Fernández, William Bernal, Ton Lisman – 29 August 2019

Elevated Fatty Liver Index as a Risk Factor for All‐Cause Mortality in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study)

Tangui Barré, Camelia Protopopescu, Firouzé Bani‐Sadr, Lionel Piroth, Teresa Rojas Rojas, Dominique Salmon‐Ceron, Linda Wittkop, Laure Esterle, Philippe Sogni, Karine Lacombe, Julie Chas, Olivia Zaegel, Marie‐Laure Chaix, Patrick Miailhes, Lawrence Serfaty, Fabienne Marcellin, Maria Patrizia Carrieri, ANRS CO13 HEPAVIH Study Group – 29 August 2019

A Prospective Trial of Withdrawal and Reinstitution of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis

Dennis D. Black, Cara Mack, Nanda Kerkar, Tamir Miloh, Shikha S. Sundaram, Ravinder Anand, Ashutosh Gupta, Estella Alonso, Ronen Arnon, Pinar Bulut, Saul Karpen, Chuan‐Hao Lin, Philip Rosenthal, Matthew Ryan, Robert H. Squires, Pamela Valentino, Sarah H. Elsea, Benjamin L. Shneider – 29 August 2019 – Ursodeoxycholic acid (UDCA) is commonly used to treat several liver disorders in adults and children, including primary sclerosing cholangitis (PSC) for which it is not U.S. Food and Drug Administration approved.

Subscribe to